On July 28, 2026, Dutch regenerative medicine firm Xeltis announced the completion of its latest financing round, raising USD 23.3 million (EUR 20.5 m
On July 8, Johnson & Johnson officially announced that its Dual‑Energy THERMOCOOL SMARTTOUCH‑SF (DE‑ST‑SF) dual‑energy ablation platform has secured US FDA clearance for market launch. It marks the world’s first interventional device enabling seamless switching between radio‑frequency ablation (RF)
On July 2, the National Medical Products Administration (NMPA) announced that it has approved the registration application for the innovative intracranial stent developed by Sino-Keno Medical Technology (Shanghai) Co., Ltd.
On July 1, Terumo Corporation, Japan’s leading medical device manufacturer, released a global recall notice to launch a simultaneous voluntary recall across all its worldwide distribution regions for specific models of its Relay™Pro Thoracic Stent-Graft System. This product, designed for endovascul
Suzhou Wushuang Medical's Silu® Implantable Cardiac Monitor (ICM) was officially approved by China's NMPA on July 1, 2026, marking the first domestically developed ICM product in China. This breakthrough fills a long-standing gap in the domestic ICM field and represents a critical milest
This article covers Neuralink’s groundbreaking transdural brain-computer interface (BCI) surgery unveiled on July 1, 2026.
The dura mater, a tough natural protective membrane covering the brain, used to be partially cut open in all traditional invasive BCI implantations, bringing high risks of infe
Stryker Corporation announced today that it has completed the acquisition of Amplitude Vascular Systems (AVS). The transaction amount was not disclosed .
In the USA and China, 30% of severe symptomatic aortic stenosis patients are inoperable. This is due to other health risks or old age. For inoperable patients, minimally invasive valve repair or replacement via a transcatheter approach is recommended.
Ultreon 3.0 uses AI and OCT to provide real-time, high-resolution imaging during minimally invasive heart procedures.
Should the transaction complete, J&J will inherit Atraverse's radiofrequency system for simplifying access to the heart's left atrium.
CEO Mike Mahoney told investors that the lowered forecast reflects challenges for several businesses, including electrophysiology and Watchman.
Discover the design and engineering story behind the company’s OmniaSecure defibrillation lead.
This new pulse sequence marks the next evolution of J&J's Varipulse Platform and is designed to improve procedural efficiency while reinforcing its established safety and effectiveness profile.
The medical device giant acquired an AI-powered coronary assessment company for $585M and led a $100M strategic round for a pulmonary hypertension therapy pioneer.
Addressing key clinical challenges: Adopting an eccentric structural design to reduce the difficulty of surgical operation and the risk of left ventricular outflow tract obstruction, while achieving stable anchoring performance and good hemodynamic performance.
Clinical data demonstrate low mortality, fewer complications and faster patient recovery with a minimally invasive alternative to open-heart surgery.
Boston Scientific's recall highlights high impedance risks in medical devices. Understand the meaning, causes, and possible solutions.
Trivia Tuesday: Ripped from the headlines 34 years before its time, what show eerily predicted Boston Scientific’s pacemaker battery problem?
